Navigation Links
A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections

MALVERN, Pa. and WALTHAM, Mass., Dec. 15 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed European infectious disease specialists with regard to their treatment of skin and skin structure infections. A drug's activity against MRSA is among the top factors that influences European physician drug selection for treating skin and skin structure infections. Other key factors that drive prescribing include an agent's skin penetration, its spectrum of activity and recommended use by national and hospital guidelines.

The new report entitled Hospital Anti-Infectives Insight Series: Skin & Skin Structure Infections (Europe) also finds that novel antibiotics in late-stage development may become useful therapeutic options for European physicians given their concern over MRSA. Two new injectable cephalosporins, Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca/Takeda's ceftaroline, offer broad-spectrum activity against MRSA and may provide convenient monotherapy options for physicians requiring broad-spectrum activity against gram-positive and gram-negative pathogens. Surveyed European specialists express willingness to use these agents in empiric therapy for complicated skin and skin structure infections, particularly in patients with suspected MRSA infections.

"Specialists we surveyed in Europe told us that they anticipate shifts in prescribing that will impact the skin structure infection market in the near future. In particular, physicians believe they will increase their empiric coverage of MRSA in complicated skin and skin structure infections," stated Decision Resources Analyst Lisa Arias. "MRSA infections are a great concern in the hospital setting and are a growing concern in the community setting because of their association with poorer outcomes and higher healthcare costs compared with non-resistant infections."

About the Report

AMR and Decision Resources' Hospital Anti-Infectives Insight Series: Skin and Skin Structure Infections (Europe) analyzes hospital antibiotic prescribing patterns in Europe using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. This report contains European data and examines the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563            

SOURCE Decision Resources; Arlington Medical Resources

SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline
2. BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in Chinas National Insurance Catalog
3. U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS
4. Reportlinker Adds Global Markets for Asthma and COPD Drugs
5., inc. Has Best Day Ever on Cyber Monday
6. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
7. Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia
8. California American Water Celebrates No Drugs Down the Drain Week in San Diego
9. Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs
10. Reportlinker Adds Chinese Markets for Respiratory Drugs
11. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... American Dental Association meeting in Washington D.C. revolved around the fact that proper dental ... health. The talk stressed the link between periodontal disease (more commonly referred to as ...
(Date:11/27/2015)... ... ... According to an article published November 15th by ABC News, while ... light of the recent terrorist attacks in Paris, other cities are taking extra precautions ... reaching U.S. soil. Especially around special events that may be high-profile in nature, the ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, ... of 750,000. The digital component is distributed nationally, through a vast social media ...
Breaking Medicine News(10 mins):